Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts.
Comprehensive and successful tuberculosis (TB) care and treatment must incorporate effective airborne infection-control strategies. This is particularly and critically important for health care workers and all persons with or at risk of human immunodeficiency virus (HIV) infection. Past and current outbreaks and epidemics of drug-susceptible, multidrug-resistant, and extensively drug-resistant TB have been fueled by HIV infection, with high rates of morbidity and mortality and linked to the absence or limited application of airborne infection-control strategies in both resource-rich and resource-limited settings. Airborne infection-control strategies are available--grouped into administrative, environmental, and personal protection categories--and have been shown to be associated with decreases in nosocomial transmission of TB; their efficacy has not been fully demonstrated, and their implementation is extremely limited, particularly in resource-limited settings. New research and resources are required to fully realize the potential benefits of infection control in the era of TB and HIV epidemics.
Shenoi
Sheela V
SV
AIDS Program, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut 06510-2483, USA.
Escombe
A Roderick
AR
Friedland
Gerald
G
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000391:Air Microbiology; D023241:Antiretroviral Therapy, Highly Active; D003428:Cross Infection / Q000517:prevention & control; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D017053:Infection Control / Q000379:methods*; D014376:Tuberculosis / Q000517:prevention & control* / Q000635:transmission*
Lancet. 2006 Nov 4;368(9547):1575-80
17084757
Int J Tuberc Lung Dis. 2007 Jun;11(6):593-605
17519089
MMWR Recomm Rep. 2009 Feb 13;58(RR-3):1-43
19214162
Public Health Rep. 2008 Jan-Feb;123(1):52-60
18348480
Curr Opin Infect Dis. 2009 Feb;22(1):11-7
19532076
PLoS Med. 2009 Mar 17;6(3):e43
19296717
Int J Tuberc Lung Dis. 2005 Aug;9(8):825
16104625
Am Rev Respir Dis. 1962 Apr;85:511-25
14492300
PLoS Med. 2007 Feb;4(2):e68
17326709
N Engl J Med. 1992 Jun 4;326(23):1514-21
1304721
J Occup Environ Hyg. 2005 May;2(5):285-92
15848970
Ann Intern Med. 1992 Aug 1;117(3):251-3
1616220
Bull World Health Organ. 1997;75(5):477-89
9447782
N Engl J Med. 1993 Feb 25;328(8):521-6
8381207
Am Rev Tuberc. 1957 Dec;76(6):931-41
13488004
Clin Infect Dis. 2007 May 15;44(10):1349-57
17443474
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7672-7
19365076
N Engl J Med. 1995 Jul 27;333(4):229-33
7791840
PLoS Med. 2008 Sep 30;5(9):e188
18798687
Infect Control Hosp Epidemiol. 1993 Nov;14(11):623-8
8132981
J Infect Dis. 2007 Aug 15;196 Suppl 1:S108-13
17624819
Int J Tuberc Lung Dis. 2008 Jun;12(6):585
18492321
MMWR Recomm Rep. 2005 Dec 30;54(RR-17):1-141
16382216
J Hosp Infect. 2004 Sep;58(1):1-13
15350707
Ann Intern Med. 2000 Nov 21;133(10):779-89
11085840
J Infect Dis. 2007 Dec 1;196 Suppl 3:S482-90
18181698
Ann Intern Med. 1992 Aug 1;117(3):191-6
1352093
Int J Tuberc Lung Dis. 2009 Apr;13(4):454-9
19335950
JAMA. 1992 Sep 9;268(10):1280-6
1507374
J Infect Dis. 2008 Dec 1;198(11):1582-9
18847372
PLoS Med. 2006 Dec;3(12):e494
17194191
Infect Control Hosp Epidemiol. 1996 Jan;17(1):11-3
8789681
Infect Control Hosp Epidemiol. 2000 Mar;21(3):191-5
10738988
Lancet. 2007 Oct 27;370(9597):1500-7
17964351
N Engl J Med. 1994 Jun 16;330(24):1710-6
7993412
Bull World Health Organ. 2002;80(7):526-31
12163915